1. American Thoracic Society. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med 2000;161:1376-1395.

2. Zuñiga M. Situación epidemiológica de la tuberculosis en Chile: evolución y perspectivas. Rev Chil Infect 1998;15(4):249-262.

3. Ledermann W. La tuberculosis después del descubrimiento de Koch. Rev Chil Infect. Edición aniversario. 2003;48-50.

4. Laval E. Sobre la transmisión de la tuberculosis y los primeros ensayos del BCG. Rev Chil Infect. Edición aniversario. 2003;51-53.

5. Fine P. BCG: The challenge continues. Scand J Infect Dis 2001;33:243-245.

6. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999;284(5419):1520-1523.

7. Haile M, Kallenius G. Recent developments in tuberculosis vaccines. Curr Opin Infect Dis 2005;18:211-215.

8. Demangel C, Garnier T, Rosenkrands I, Cole ST. Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens. Infect Immun 2005;73(4):2190-2196.

9. de Lisle GW, Wards BJ, Buddle BM, Collins DM. The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium. Tuberculosis (Edinb) 2005;85(1-2):73-79.

10. Martin C. Tuberculosis vaccines: past, present and future. Curr Opin Pulm Med 2006;12:186-191.

11. Young D, Dye C. The Development and Impact of Tuberculosis Vaccines. Cell 2006;124(4):683-687.

12. Farga V. Tuberculosis. 2° Edición. Editorial Mediterráneo. Septiembre de 1998.

13. Buddle BM, Wards BJ, Aldwell FE, Collins DM, de Lisle GW. Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. Vaccine 2002;20(7-8):1126-1133.

14. Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA 2004;291(17):2086-2091.

15. Infuso A, Falzon D; EuroTB network. European survey of BCG vaccination policies and surveillance in children, 2005. Euro Surveill 2006;11(3):6-11.

16. National Advisory Committee on Immunization of Canada. Statement on Bacille Calmette Guérin (BCG) vaccine. Canada Communicable Disease Report 2004;30:1-12.

17. Barreto ML, Pereira SM, Ferreira AA. BCG vaccine: efficacy and indications for vaccination and revaccination. J Pediatr (Rio J) 2006;82(3 Suppl):S45-54.

18. Voss L. BCG Vaccination. En: Guidelines for Tuberculosis Control in New Zealand 2003;Capítulo 8.

19. Carrizo JT. Vacuna de bacilos Calmette-Guérin. BCG. Archivos venezolanos de Puericultura y Pediatría 2000;63(3 Suppl):S16-19.

20. Singla A, Singh S, Goraya JS, Radhika S, Sharma M. The natural course of nonsuppurative Calmette-Guerin bacillus lymphadenitis. Pediatr Infect Dis J 2002;21(5):446-448.

21. Goraya JS, Virdi VS. Treatment of Calmette-Guerin bacillus adenitis, a metaanalysis. Pediatr Infect Dis J 2001;20:632-634.

22. Oguz F, Mujgan S, Alper G, Alev F, Neyzi O. Treatment of bacillus Calmette-Guerin-associated lymphadenitis. Pediatr Infect Dis J 1992;11:887-888.

23. Barbaud A. Réactions cutanées retardées dues aux vaccins. En: Vaccins: intolerance et allergie. Nicolas JF, Kaiserlian D, Bérard F. Ed. John Libbey, Paris. 2003 p. 123-143.

24. Casanova JL, Blanche S, Emile JF, Jouanguy E, Lamhamedi S, Altare F, et al. Idiopathic disseminated bacille Calmette-Guérin infection: a French national retrospective study. Pediatrics 1996;98(4 pt 1):774-778.

25. Schattner A, Gilad A, Cohen J. Systemic granulomatosis and hypercalcemia following intravesical bacillus Calmette-Guérin immunotherapy. J Intern Med 2002;251:272-277.

26. Rosenthal SR, Loewinsohn E, Graham, Liveright D, Thorne G, Johnson V. BCG vaccination against tuberculosis in Chicago. A twenty year study statistically. Pediatrics. 1961;28:622-641.

27. Cheson B. BCG therapy and urticaria. Ann Intern Med 1975;82:738.

28. Hedin H, Richter W. Dextran-induced anaphylactoid reactions in man. Role of dextran-reactive antibodies. Int Arch Allergy Appl Immunol 1976;52:145-159.

29. Ponvet C, Scheinmann P. Les réactions vaccinales allergiques et pseudoallergiques de chronologie immediate et accélérée. En: Vaccins: intolerance et allergie. Nicolas JF, Kaiserlian D, Bérard F. Ed. John Libbey, Paris. 2003 p. 109-121.

30. Kass E, Straume S, Mellebye O, Munthe E, Solheim B. Dermatomyositis associated with BCG vaccination. Scand J Rheumatol 1979;8:187-191.

31. Misery L, Combemale P. BCG vaccine-induced lupus vulgaris and urticarial vasculitis. Dermatology 1993;186:274.

32. Barbaud A, Schmutz JL, Mougeolle JM. Reactions immuno-allergiques cutanées dues aux vaccines. Ann Dermatol Venereol 1995;122:129-138.

33. Radeff B, Harms M. Acute febrile neutrophilic dermatosis (Sweet´s syndrome) following BCG vaccination. Acta Derm Veneorol 1986;66:357.

34. Izumi A, Matsunaga J. BCG-vaccine induced lupus vulgaris. Arch Dermatol 1982;118:171-172.

35. Sehgal V, Hain S, Gupta R. Inoculation lupus vulgaris. J Dermatol 1992;19:58-60.

36. Dangoisse CH, Song M. Conduite a tenir devant les complications cutanées du BCG. Ann Dermatol Venereol 1990;117:45-51.

37. Aftimos S, Nicol R. BCG osteitis: a case report. N Z Med J 1986;99:271-273.

38. Schopfer K, Matter L, Brunner C, Pagon S, Stanisic M, Baerlocher K. BCG osteomyelitis. Case report and review. Helv Paediatr Acta 1982;37:73-81.

39. Khotaei GT, Sediqhipour L, Fattahi F, Pourpak Z. Osteomyelitis as a late complication of Bacille Calmette-Guerin vaccine. J Microbiol Immunol Infect Dis 2006;39:169-172.

40. Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, et al.Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 2005;85(1-2):29-38.

41. Nor M., Musa M. Approaches towards the development of a vaccine against tuberculosis: recombinant BCG and DNA vaccine. Tuberculosis 2004;84:102-109.

42. Horwitz MA. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect 2005;7:947–954.

43. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003;9(5):533-539.

44. Grode L, Seiler P, Baumann S, Hess J, Brinckmann V, Nasser Eddine A, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005;115(9):2472–2479.

45. Kaplan G. Rational Vaccine Development – A New Trend in Tuberculosis Control. N Engl J Med 2005;353(15):1624-1625.

46. Orme I, McMurray D, Belisle J. Tuberculosis vaccine development: recent progress. TRENDS in Microbiology 2001;9(3):115-118.

47. Irwin SM, Izzo AA, Dow SW, Skeiky YA, Reed SG, Alderson MR, et al. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun 2005;73(9):5809-16.

48. Haile M, Schroder U, Hamasur B, Pawlowski A, Jaxmar T, Kallenius G, et al. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. Vaccine 2004;22(11-12):1498-508.

49. Chambers MA, Wright DC, Brisker J, Williams A, Hatch G, Gavier-Widen D, et al. A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome) protects guinea pigs from lethal tuberculosis. Vaccine 2004;22(8):1063-71.

50. Doherty TM, Olsen AW, van Pinxteren L, Andersen P. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect Immun 2002;70(6):3111-3121.

51. Lagranderie M, Chavarot P, Balazuc AM, Marchal G. Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice. Vaccine 2000;18(13):1186-1195.

52. Lagranderie M, Nahori MA, Balazuc AM, Kiefer-Biasizzo H, Lapa e Silva JR, Milon G et al. Dendritic cells recruited to the lung shortly after intranasal delivery of Mycobacterium bovis BCG drive the primary immune response towards a type 1 cytokine production. Immunology 2003;108(3):352-364.

53. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003;171(3):1602-9.

54. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004;173(10):6357-6365.

55. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004;10(11):1240–1244.

56. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346(8986):1339-1345.

57. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271(9):698-702

Para descargar el PDF del artículo
Vacunas en tuberculosis

Haga click aquí